224 related articles for article (PubMed ID: 38170178)
1. Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.
Vadivel CK; Willerslev-Olsen A; Namini MRJ; Zeng Z; Yan L; Danielsen M; Gluud M; Pallesen EMH; Wojewoda K; Osmancevic A; Hedebo S; Chang YT; Lindahl LM; Koralov SB; Geskin LJ; Bates SE; Iversen L; Litman T; Bech R; Wobser M; Guenova E; Kamstrup MR; Ødum N; Buus TB
Blood; 2024 Apr; 143(15):1496-1512. PubMed ID: 38170178
[TBL] [Abstract][Full Text] [Related]
2. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome.
Willerslev-Olsen A; Buus TB; Nastasi C; Blümel E; Gluud M; Bonefeld CM; Geisler C; Lindahl LM; Vermeer M; Wasik MA; Iversen L; Becker JC; Andersen MH; Gjerdrum LMR; Litvinov IV; Litman T; Krejsgaard T; Woetmann A; Ødum N
Blood Cancer J; 2020 May; 10(5):57. PubMed ID: 32409671
[TBL] [Abstract][Full Text] [Related]
3. Keratinocytes present Staphylococcus aureus enterotoxins and promote malignant and non-malignant T cell proliferation in cutaneous T cell lymphoma.
Zeng Z; Vadivel CK; Gluud M; Namini MRJ; Yan L; Ahmad S; Hansen MB; Coquet J; Mustelin T; Koralov SB; Bonefeld CM; Woetmann A; Geisler C; Guenova E; Kamstrup MR; Litman T; Gjerdrum LR; Buus TB; Ødum N
J Invest Dermatol; 2024 May; ():. PubMed ID: 38762064
[TBL] [Abstract][Full Text] [Related]
4. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
[TBL] [Abstract][Full Text] [Related]
5. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Sors A; Jean-Louis F; Pellet C; Laroche L; Dubertret L; Courtois G; Bachelez H; Michel L
Blood; 2006 Mar; 107(6):2354-63. PubMed ID: 16219794
[TBL] [Abstract][Full Text] [Related]
6. Single-cell heterogeneity in Sézary syndrome.
Buus TB; Willerslev-Olsen A; Fredholm S; Blümel E; Nastasi C; Gluud M; Hu T; Lindahl LM; Iversen L; Fogh H; Gniadecki R; Litvinov IV; Persson JL; Bonefeld CM; Geisler C; Christensen JP; Krejsgaard T; Litman T; Woetmann A; Ødum N
Blood Adv; 2018 Aug; 2(16):2115-2126. PubMed ID: 30139925
[TBL] [Abstract][Full Text] [Related]
7. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.
Kiessling MK; Klemke CD; Kaminski MM; Galani IE; Krammer PH; Gülow K
Cancer Res; 2009 Mar; 69(6):2365-74. PubMed ID: 19258503
[TBL] [Abstract][Full Text] [Related]
9. Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma.
Willerslev-Olsen A; Gjerdrum LMR; Lindahl LM; Buus TB; Pallesen EMH; Gluud M; Bzorek M; Nielsen BS; Kamstrup MR; Rittig AH; Bonefeld CM; Krejsgaard T; Geisler C; Koralov SB; Litman T; Becker JC; Woetmann A; Iversen L; Odum N
J Invest Dermatol; 2021 Oct; 141(10):2449-2458. PubMed ID: 33862068
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens.
Tokura Y; Yagi H; Ohshima A; Kurokawa S; Wakita H; Yokote R; Shirahama S; Furukawa F; Takigawa M
Br J Dermatol; 1995 Jul; 133(1):6-12. PubMed ID: 7669641
[TBL] [Abstract][Full Text] [Related]
11. Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma.
Pallesen EMH; Gluud M; Vadivel CK; Buus TB; de Rooij B; Zeng Z; Ahmad S; Willerslev-Olsen A; Röhrig C; Kamstrup MR; Bay L; Lindahl L; Krejsgaard T; Geisler C; Bonefeld CM; Iversen L; Woetmann A; Koralov SB; Bjarnsholt T; Frieling J; Schmelcher M; Ødum N
J Invest Dermatol; 2023 Sep; 143(9):1757-1768.e3. PubMed ID: 36889662
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
13. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins.
Woetmann A; Lovato P; Eriksen KW; Krejsgaard T; Labuda T; Zhang Q; Mathiesen AM; Geisler C; Svejgaard A; Wasik MA; Ødum N
Blood; 2007 Apr; 109(8):3325-32. PubMed ID: 17179233
[TBL] [Abstract][Full Text] [Related]
14. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.
Willerslev-Olsen A; Krejsgaard T; Lindahl LM; Bonefeld CM; Wasik MA; Koralov SB; Geisler C; Kilian M; Iversen L; Woetmann A; Odum N
Toxins (Basel); 2013 Aug; 5(8):1402-21. PubMed ID: 23949004
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
16. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion.
Jackow CM; Cather JC; Hearne V; Asano AT; Musser JM; Duvic M
Blood; 1997 Jan; 89(1):32-40. PubMed ID: 8978274
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
[TBL] [Abstract][Full Text] [Related]
19. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Trager MH; Geskin LJ
G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
[TBL] [Abstract][Full Text] [Related]
20. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Willerslev-Olsen A; Krejsgaard T; Lindahl LM; Litvinov IV; Fredholm S; Petersen DL; Nastasi C; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Kilian M; Koralov SB; Odum N
Blood; 2016 Mar; 127(10):1287-96. PubMed ID: 26738536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
